Agennix AG

Agennix AG

Agennix develops oral, topical, and other forms of cancer treatments. The company's primary candidate, Talactoferrin, is an oral therapy in the late stages of development that is targeted to treat non-small cell lung cancer, a common and slow-growing type of lung cancer. Its other clinical development-stage candidates include therapies to treat tumors and prostate cancer, as well as non-cancerous conditions such as sepsis and diabetic foot ulcers. Agennix, which has offices in Munich, Germany; Princeton, New Jersey; and Houston, Texas, was formed in 2009 from the merger of Germany-based GPC Biotech AG and US-based Agennix Inc.

Contact Details

Office Address

Agennix AG
Fraunhoferstrasse 20
Planegg/Martinsried, Munich, Germany 82152
Phone: +49-89-85-65-2600
Fax: +49-89-85-65-2610

Executives

Chairman

Christof Hettich

Interim CEO

Friedrich von Bohlen und Halbach

Business Reviews for Agennix AG

Related Companies